{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:01:45Z","timestamp":1791273705986,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T00:00:00Z","timestamp":1391040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T00:00:00Z","timestamp":1391040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1038\/leu.2014.49","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T07:41:32Z","timestamp":1391067692000},"page":"1374-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis"],"prefix":"10.1038","volume":"28","author":[{"given":"J","family":"Bros\u00e9us","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Harutyunyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Zipperer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Florensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Lu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schnittger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kralovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Girodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,30]]},"reference":[{"key":"BFleu201449_CR1","first-page":"85","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"JW Vardiman","year":"2008","unstructured":"Vardiman JW, Bennet JM, Bain BJ, Baumann I, Thiele J, Orazi A . Myelodysplastic\/myeloproliferative neoplasm, unclassifiable. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn IARC: Lyon, France, 2008; pp 85\u201386."},{"key":"BFleu201449_CR2","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/sj.leu.2404405","volume":"20","author":"A Renneville","year":"2006","unstructured":"Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, La\u00ef JL et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067\u20132070.","journal-title":"Leukemia"},{"issue":"12 Suppl","key":"BFleu201449_CR3","first-page":"ECR57","volume":"91","author":"DP Steensma","year":"2006","unstructured":"Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A . MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica 2006; 91 (12 Suppl): ECR57.","journal-title":"Haematologica"},{"key":"BFleu201449_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","volume":"97","author":"J Broseus","year":"2012","unstructured":"Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012; 97: 1036\u20131041.","journal-title":"Haematologica"},{"key":"BFleu201449_CR5","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472\u20133476.","journal-title":"Blood"},{"key":"BFleu201449_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/sj.leu.2404909","volume":"22","author":"S Schnittger","year":"2008","unstructured":"Schnittger S, Bacher U, Haferlach C, Dengler R, Kr\u00f6ber A, Kern W et al. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia 2008; 22: 453\u2013455.","journal-title":"Leukemia"},{"key":"BFleu201449_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/leu.2011.232","volume":"26","author":"V Visconte","year":"2012","unstructured":"Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542\u2013545.","journal-title":"Leukemia"},{"key":"BFleu201449_CR8","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384\u20131395.","journal-title":"N Engl J Med"},{"key":"BFleu201449_CR9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/leu.2013.120","volume":"27","author":"J Broseus","year":"2013","unstructured":"Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27: 1826\u20131831.","journal-title":"Leukemia"},{"key":"BFleu201449_CR10","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFleu201449_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391\u20132405.","journal-title":"N Engl J Med"},{"key":"BFleu201449_CR12","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","volume":"108","author":"E Lippert","year":"2006","unstructured":"Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865\u20131867.","journal-title":"Blood"},{"key":"BFleu201449_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3324\/haematol.13223","volume":"94","author":"S Schnittger","year":"2009","unstructured":"Schnittger S, Bacher U, Haferlach C, Geer T, M\u00fcller P, Mitterm\u00fcller J et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica 2009; 94: 414\u2013418.","journal-title":"Haematologica"},{"key":"BFleu201449_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3324\/haematol.13224","volume":"94","author":"S Schnittger","year":"2009","unstructured":"Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, B\u00fcrkle D et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2009; 94: 141\u2013144.","journal-title":"Haematologica"},{"issue":"7","key":"BFleu201449_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; e-pub ahead of print 21 January 2014 doi:10.1038\/leu.2014.3.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201449","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:11:53Z","timestamp":1648743113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,30]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["BFleu201449"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.49","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,30]]},"assertion":[{"value":"30 January 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS and TH declare part ownership of the MLL Munich Leukemia Laboratory. SJ is employed by the MLL Munich Leukemia Laboratory. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}